Rothschild & Co Asset Management US’s Acorda Therapeutics ACOR Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,657	Closed	-$11.7M	–	593
2017 Q1	$11.7M	Buy	4,657 +99	+2%	+$285K	0.13%	227
2016 Q4	$10.3M	Buy	4,558 +684	+18%	+$1.63M	0.13%	232
2016 Q3	$9.71M	Buy	3,874 +246	+7%	+$734K	0.17%	218
2016 Q2	$11.1M	Buy	3,628 +478	+15%	+$1.55M	0.2%	189
2016 Q1	$10M	Buy	3,150 +189	+6%	+$785K	0.19%	185
2015 Q4	$15.2M	Buy	2,961 +161	+6%	+$704K	0.28%	114
2015 Q3	$8.91M	Buy	2,800 +595	+27%	+$2.31M	0.17%	197
2015 Q2	$8.82M	Buy	2,205 +32	+1%	+$124K	0.16%	209
2015 Q1	$8.68M	Buy	2,173 +1,352	+165%	+$6.19M	0.16%	208
2014 Q4	$4.03M	Buy	821 +5	+0.6%	+$21.5K	0.08%	275
2014 Q3	$3.32M	Sell	816 -34	-4%	-$128K	0.07%	292
2014 Q2	$3.44M	Sell	850 -22	-3%	-$89.7K	0.07%	302
2014 Q1	$3.97M	Sell	872 -1,450	-62%	-$5.86M	0.09%	301
2013 Q4	$8.14M	Buy	2,322 +24	+1%	+$93.6K	0.18%	204
2013 Q3	$9.43M	Sell	2,298 -1	-0%	-$4.31K	0.21%	168
2013 Q2	$9.1M	Buy	+2,299	New	+$9.47M	0.21%	164

Other funds holding ACOR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Rothschild & Co Asset Management US's ACOR Position: Q2 2017 in Review

Rothschild & Co Asset Management US sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 4,657 shares — an estimated $11.7M sold.

Rothschild & Co Asset Management US first reported a position in ACOR in Q2 2013 and held it in 16 quarters. The position peaked at $15.2M in Q4 2015. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

Rothschild & Co Asset Management US reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
Rothschild & Co Asset Management US sold 4,657 Acorda Therapeutics shares in Q2 2017, an estimated $11.7M.
Rothschild & Co Asset Management US first reported a position in Acorda Therapeutics in Q2 2013 and held it in 16 quarters.
Rothschild & Co Asset Management US's Acorda Therapeutics position peaked at $15.2M in Q4 2015.
151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on Rothschild & Co Asset Management US's 13F filing for Q2 2017, filed 27 Jul 2017.